

Research on the formation of *Pseudomonas aeruginosa* biofilms as a factor in the development of antibiotic resistance in fatal pneumonias

Maryna Mishyna¹, Alfredo Chetta², Olha Bondarenko^{1,2}, Svitlana Malanchuk³, Mykhailo Mishyn⁴, Yuliya Mozgova¹, Iryna Marchenko¹, Roberta Pisi², Annalisa Frizzelli², Yurii Kot³

¹Department of Microbiology, Virology and Immunology named after D.P. Grynyov, Kharkiv National Medical University, Kharkiv, Ukraine; ²Department of Medicine and Surgery, University of Parma, Parma, Italy; ³Department of Infectious Diseases and Clinical Immunology; Department of Biochemistry, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine; ⁴Kharkiv regional bureau of forensic medical examination, Kharkiv, Ukraine.

Abstract. *Background and aim:* Antibiotic resistance of community-acquired pneumonia pathogens and the emergence of multiresistant bacteria is a problem of global importance. Determining the ability to form biofilms will provide an opportunity to develop new ways to overcome bacterial resistance to antimicrobial drugs. Thus, this study aimed to determine *Pseudomonas aeruginosa* isolates antibiotic resistance and to study the architecture of its biofilms. *Methods:* 22 fatal cases of secondary pneumonia due to gunshot trauma for the period from 2022 to 2023 during the war in Ukraine were studied. Isolation and identification of pure culture were provided using Micro-la-test kits. The sensitivity to antimicrobial drugs was studied using «SENSILAt-test G-I, G-II» and Kirby-Bauer Disk Diffusion Susceptibility Test. To form biofilms bacteria was grown on the surface of coverslips in the 35 mm Petri dishes for 24 h. Biofilm formation was assessed by laser scanning confocal microscopy and scanning electron microscopy. *Results:* Examination of biological samples revealed 22 strains of microorganisms. Gram-negative microorganisms predominated among pathogens (63.6%) and *Pseudomonas aeruginosa* isolates were 50%. Determining the sensitivity established that to antimicrobial drugs took place in 71.4% of cases (5 strains), and poly-resistance was found in 28.6% of cases (2 strains). *Conclusions:* the study of structural and functional features of biofilm formation showed that biofilms were formed according to classical stages. Dense biofilms determined the phenotypic variability of *Pseudomonas aeruginosa* with the development of antibiotic resistance to antimicrobial drugs, which is a barrier to the use of antimicrobial therapy. (www.actabiomedica.it)

Key words: pneumonia, antibiotic resistance, isolates of *Pseudomonas aeruginosa*, biofilms

Introduction

Antibiotic resistance (antimicrobial resistance) and the emergence of multidrug-resistant bacterial strains are problems of global importance that pose serious threats to humanity. Today the situation in

Ukraine, as in the world as a whole, is disappointing. The main reason is considered to be the irrational use of antibacterial therapy, because it leads to the selection of chemoresistant pathogen strains (1).

According to the World Health Organization, antibiotic resistance is one of the world's 10 main

threats to human health. It is predicted that by 2050 infections, caused by antibiotic-resistant microorganisms, may cause about 10 million annual deaths. The range of bacteria that become resistant to any known antimicrobial is steadily increasing (2).

Pneumonia is an acute infectious disease of mainly bacterial aetiology, which is characterized by focal lesions of the lungs and the obligatory presence of intra-alveolar exudation. A distinction is made between community-acquired pneumonia (CAP), i.e. outside a medical institution and in-hospital (nosocomial) pneumonia. CAP is the prominent cause of mortality and morbidity with an important clinical impact across the globe (3, 4).

Today pneumonia is mostly caused by gram-negative bacteria, in particular *Pseudomonas aeruginosa*. The main problem of treating such pneumonia is related to drug resistance, which is due to the ability of bacteria to form biofilms as a factor in the phenotypic variability of the pathogen (5, 6).

Bacteria in the biofilm state develop specific communications called quorum sensing (QS) (7, 8). Thus, the QS of *P. aeruginosa* regulates the production of virulence factors, such as extracellular exopolysaccharides, proteases and phenazines, which determine the processes of adhesion, colonization and dissemination of the pathogen (9-12). Thus, *P. aeruginosa*, using QS, develops resistance to various groups of antibiotics, including aminoglycosides, quinolones, carbapenems and β -lactams (13-17). The spread of antibiotic-resistant bacteria in hospitals and community-acquired infections is one of the main problems of antibiotic therapy (18, 19).

One of the leading mechanisms of the development of bacterial pneumonia is infection with antibiotic-resistant strains of the macroorganism with suppression of the immune status as a result of gunshot and shrapnel injuries. At the same time, the persistence of bacteria in the patient's body in the form of dense biofilms, which is the main factor in the pathogenicity and virulence of *P. aeruginosa* is important (20, 21). In fact, this leads to the inactivation of natural anti-infective resistance factors, such as the systems of complement, lysozyme, platelet cationic protein, etc. (23). The ability of microorganisms to survive antibiotic

therapy is determined by their indifference to physico-chemical factors and acquisition of resistance to host defense mechanisms (24, 25).

Cellular mechanisms of non-specific protection play an important role mainly in the respiratory part of the lungs. The main cells here are leukocytes, neutrophils, eosinophils and macrophages. During massive bacterial aggression, these cells release such chemokines as Il-8, TNF- α , Il-1, components of the complement system, as well as G-CSF, which is important in the development of pneumonia (26-28). Humoral protective factors are provided by immunoglobulins A and G, lymphoid cells, macrophages of lymphoid tissue and lymph nodes of the lungs and bronchi (29). Ig A provides agglutination of bacteria and neutralizes their toxins. Ig G in the lower respiratory tract agglutinates and opsonizes bacteria, and activates the complement system, due to which the chemotaxis process of neutrophils and macrophages is accelerated. But when these defense mechanisms are violated, the emergence of an infectious process becomes possible. Thus, when mucus secretion is impaired, the process of adhesion of bacteria to epithelial cells is facilitated. This leads to damage to the latter and increased adhesion of the pathogen, followed by the formation of dense biofilms, which is the main factor in the pathogenicity and virulence of bacteria. This is the pattern of a vicious circle of colonization formation (30-36).

Therefore, bacteria can adapt to environmental changes, including exposure to low and high doses of antibiotics and use such resistance mechanisms as reduced membrane permeability, the presence of drug efflux pumps and their enzymatic inactivation and in addition the spread of antibiotic resistance genes due to the mobility of genetic factors (37, 38). The problem of developing of antibiotic resistance of *P. aeruginosa*, as a factor in types of pneumonia that lead to death, requires more thorough and in-depth research, namely, detailing the stages of biofilm formation (39-41).

The aim of this study is to determine the mechanism underlying the resistance of *P. aeruginosa* isolates to antibiotic drugs and study the architecture of the biofilm formed by multi-resistant isolates as a factor in the protection of bacteria against antibiotics.

Material and Methods

Study design and subjects

The research was carried out as part of a scientific research project «Experimental substantiation of antimicrobial agent complex application based on determination of peculiarities of microbiological properties of pathogens of purulent-inflammatory diseases» (№ 0120U102569, 2020-2024) of the Department of Microbiology, Virology and Immunology named after Prof. D.P. Grynyov. In this study biological cadaveric material of military personnel with gunshot injuries and community-acquired pneumonia was collected from corpses stored in the hospital's morgue. Their medical records were studied retrospectively. At the time of hospitalization, all patients were examined according to the protocol for the treatment of pneumonia: chest x-ray, clinical sputum analysis, sputum analysis for *Mycobacterium tuberculosis*, sputum culture to determine sensitivity to antibiotics, standard clinical and biochemical analysis of blood and urine, C-reactive protein, D - dimer, procalcitonin, bacterial culture of blood for sterility, bronchoscopy if indicated. An informed written consent was obtained from the patients' relatives prior to the study.

Microbiology testing

For microbiological research, the kits that enable the identification of clinical strains were used. The tests are placed in the wells of a segmented microtitration plate.

The sensitivity of clinical strains of microorganisms to antimicrobial drugs was studied using Kirby-Bauer Disk Diffusion Susceptibility Test (a standardized protocol to test whether particular bacteria are susceptible to a known concentration of certain antibiotics) and kits "MIC G-I, G-II" (Czech Republic). MIC G-I, G-II tests are designed to test the antimicrobial susceptibility of bacteria from the Enterobacteriaceae family based on the determination of the lowest concentration of certain antibiotics, which inhibits bacterial growth. Both kits are recommended to be used together to test susceptibility to

antibiotics used in the treatment of serious infections, especially in hospitalized patients.

Isolation and identification of a pure culture of pneumonia pathogens were carried out using Micro-la-test kits (Czech Republic). The sensitivity of clinical strains of microorganisms to antimicrobial drugs was studied using a microtest system with semiquantitative registration of results "SENSILA test G-I, G-II" and Kirby-Bauer Disk Diffusion Susceptibility Test. Biofilms were grown in Petri dishes on glass coverslips.

Scanning electron microscopy

Samples were imaged with a field emission scanning electron microscope Vega 3 LMH (Tescan).

Laser scanning confocal microscopy (LSCM)

Intravital cell viability was assessed by LSCM after fluorescence staining nucleoid DNA with DAPI/PI-based «*Bacstain* Bacterial Viability Detection Kit» (Dojindo, Cat. No. BS08). DAPI dye (λ_{Ex} – 405 nm, λ_{Em} – 461 nm) is a minor groove binder specific to the AT sequence of DNA and permeates into bacteria to stain nucleic acids regardless of membrane damage. PI (λ_{Ex} – 493 nm, λ_{Em} = 636 nm) is a parallel intercalator into the DNA double helix that stains nucleic acid which passes only through damaged bacterial membranes. The samples were stained for 15 minutes in the dark. Bacteria-associated and extracellular polysaccharide matrix was label-free visualized by green autofluorescence (λ_{Ex} – 488 nm, λ_{Em} – 532 nm). Live-cell imaging was conducted using an Olympus FV10i-LIV LSCM equipped with a 60/1.2 NA water immersion lens. Confocal images were acquired with a scanning mode format of 1024×1024 pixels. The pinhole aperture was 1 Airy unit. Z-reconstruction of serial single optical sections was performed with a scanning mode of 1024×1024 pixels with an electronic zoom at 2.0 and a Z stack of 0.2 $\mu\text{m}/\text{slice}$. The shown confocal images are representative images of ten fields of view in different regions of the coverslip. Post-rendering of the obtained images of optical sections was performed using Olympus excellence software (Olympus licensed).

The imaging was carried out in triplicates with three independent repetitions.

Statistical data

Data were compared using the Mann-Whitney test. If more than two variables were compared, the Dunn's and Kruskal-Wallis tests were used. The difference between variables was considered statistically significant if p values did not exceed 0,005.

This study was approved by the meeting of the Department of Microbiology, Virology and Immunology named after D.P.Grynyov, Kharkiv National Medical University (Protocol No.2, 01/30/2024).

Results

The biological material of 22 military (21 men), aged between 30-50 years was studied. The patients were hospitalized with a diagnosis of gunshot wound, bilateral community-acquired pneumonia, pulmonary and cardiac failure of the 3-4th degree. 27% of patients did not have the classic symptoms of pneumonia (fever, dyspnoea, cough), which led to a delay in diagnosis at the prehospital level. In two patients, the disease progressed from local infection (lung wound) to systemic infection with a spectrum of complications associated with the development of sepsis (SCAP). That required admission to the intensive care unit with prolonged

artificial ventilation of the lungs for more than 7 days. These patients had a history of chronic obstructive pulmonary disease. All patients diagnosed with CAP received combined antibiotic therapy, mucolytics and detoxification therapy. It was a combination of 3-4th generation quinolones with 3-4th generation of cephalosporin. Upon transition to stage 4th of pneumonia, meropenem group of drugs was prescribed. SpO₂ < 85-88% was an indication for oxygen therapy.

At the time of admission, 73% of patients had profuse sputum, but only 27% of them underwent bacterial examination of sputum in the prehospital phase (outpatient type of facility).

The bacteriological analysis of biological material in the case of CAP showed that gram-negative microorganisms (63.6%), more often *P. aeruginosa*, predominate among the detected pathogens.

During the study of biological samples of patients, 22 strains of microorganisms were detected (Figure 1). Non-fermenting gram-negative aerobic rod-shaped microorganisms *P. aeruginosa* were cultured in 31.8% of cases (in the amount of $1 \times 10^{8-9}$ CFU, Figure 2). Gram-negative facultatively anaerobic bacteria *Klebsiella pneumoniae* was isolated in 18.2% of cases (in the amount of $1 \times 10^{6-8}$ CFU). *Escherichia coli* was detected in 9.1% of cases (in the amount of $1 \times 10^{4-8}$ CFU) and gram-negative, immobile facultatively anaerobic capnophilic pathogenic bacterium *Haemophilus influenzae* was found in 4.5% of cases (in the amount of 1×10^8 CFU). Gram-positive bacteria were represented by:




Figure 1. Composition of etiological factors (absolute number of strains) of community-acquired bacterial pneumonia from patients' biological samples.




Figure 2. Isolates of *P. aeruginosa*.




Figure 3. Determining the sensitivity of *P. aeruginosa* isolates to antimicrobial drugs by the Kirby-Bauer Disk Diffusion Susceptibility Test method.

Streptococcus pyogenes in 13.7% of cases (in the amount of $1 \times 10^{6-9}$ CFU), *Staphylococcus aureus* (in the amount of $1 \times 10^{5-8}$ CFU) and *Streptococcus pneumoniae* (in the amount of $1 \times 10^{6-8}$ CFU) in 9.1% each, *Staphylococcus epidermidis* in 4.5% of cases (in the amount of 1×10^6 CFU).

Determining the sensitivity of *P. aeruginosa* isolates to antimicrobial drugs showed that all isolates were resistant to: Amikacin (AMK), Ampicillin (AMP), Ampicillin/sulbactam (AMS), Cefalexin (CEX), Cefuroxime (CXM), Cefotaxime (CTX), Ciprofloxacin (CIP), Gentamicin (GEN), Trimetoprim/sulfamethoxazole (T/S), Aztreonam (AZT), Cefazidime (CAZ), Ceftazidime/clavulanate (CZC), Cefepime (CEP), Meropenem (MER), Netilmicin (NET), Piperacilin/tazobactam (PIT), Tigecyclin (TGC) (Figure 3). For example, the aminoglycoside antibiotic (AMK) and quinolone (CIP) demonstrated reduced diffusion through *P. aeruginosa* biofilm models, similar to the effects of β -lactam antibiotics.

Studying the structural and functional features of biofilm formation by multi-resistant isolates of *P. aeruginosa* using scanning microscopy established

that the adhesion of individual bacterial cells occurs with the subsequent formation of conglomerates surrounded by a matrix with the subsequent formation of a biofilm (Figure 4). The process of irreversible fixation lasts from 12 to 14 hours for poly-resistant strains of *P. aeruginosa* and from 14 to 18 hours for pan-resistant isolates. Generally, the process of primary biofilm formation lasts from 16 to 20 hours for poly-resistant strains of *P. aeruginosa* and from 18 to 24 hours for pan-resistant isolates from the beginning of adhesion.

Bacterial cells arranged in the form of dense elongated sticks were visible under the film. It was found that daily biofilms of *P. aeruginosa* isolates have a dense structure in the form of a gel.

With the help of luminescence microscopy, it were revealed dense areas of biofilm, in which the accumulation of cells with high luminescence was indicated (Figure 5).

As a result of the quantitative analysis of the conducted study, it was established that poly-resistant isolates of *P. aeruginosa* formed biofilms, the density of which was 2.48 ± 0.14 optical density (OD) and in pan-resistant isolates it was 4.16 ± 0.18 OD.




Figure 4. *P. aeruginosa* biofilm formation: I stage - adhesion of isolates; II stage - fixation; III stage - co-aggregation; IV stage - clustering.




Figure 5. Ability of *P. aeruginosa* to form biofilms. A – biofilm of poly-resistant strains of *P. aeruginosa*; B – biofilm of pan-resistant strains of *P. aeruginosa*.

The LSCM analysis (Figure 6, Figure 7) depicts live bacteria with intact membranes in blue (DAPI blue-fluorescent nucleic acid stain) whereas, non-viable bacteria with damaged membranes incorporate propidium iodide (red-fluorescent nucleic acid stain) and are stained red. For analysis single slices (thickness 0.2 μm) of a confocal stack were provided. In 24 h-old biofilm indicated high viability (>95%) and uninhibited biofilm formation without membrane damage.

LSCM visualized *P. aeruginosa* cells forming a 24 h-old layer on the surface of the coverslip. Single slices (thickness 0.2 μm) of a confocal stack were provided. Composite image of green, blue and red emission bands: green fluorescence (polysaccharide matrix autofluorescence) was excited with 488 nm; blue fluorescence (nucleoid DNA+DAPI) was excited with 405 nm and red fluorescence (damaged cells nucleoid DNA+PI) was excited with 493 nm. Scale bar = 2 μm was used.

LSCM provided a three-dimensional reconstruction of a 24 hours-old biofilm layer of *P. aeruginosa* cells, created from a confocal stack of Olympus cellSence software (Figure 7). Composite image of green, blue

and red emission bands: green fluorescence (polysaccharide matrix autofluorescence excited with 488 nm); blue fluorescence (nucleoid DNA+DAPI excited with 405 nm) and red fluorescence (fluorescence of the damaged nucleoid DNA+PI excited with 493 nm).

The primary functions of cell-associated and cell-free produced polysaccharide matrix are to hold the bacterial community together, fix bacterial cells to solid surfaces, and maintain proper hydration and nutrients availability. However, polysaccharide matrix plays a key role in the formation of biofilm and also in biofilm resistance to antimicrobial agents and protects bacteria from stresses like desiccation and oxidizing agents (42). The LSCM imaging demonstrated that biofilm-forming bacteria embedded in polymeric extracellular matrices that consist of thick polysaccharides layer.

Discussion

In the management of CAP patients, assessment of severity is fundamental not only to assign the




Figure 6. LSCM visualization of *P. aeruginosa* cells forming a 24 hours-old layer on the surface of the coverslip. A – multicolor imaging of bacterial polysaccharide matrix and nucleoids; B – bacterial nucleoid imaging.




Figure 7. LSCM three-dimensional reconstruction of a 24 hours-old biofilm layer of *P. aeruginosa* cells. A – multicolor imaging of bacterial polysaccharide matrix and nucleoids; B – imaging of nucleoids only.

appropriate site of care but also to select empiric antibiotic therapy.

In the current study, the laboratory-microbiological aspects of *P. aeruginosa* biofilms formation as a factor in the development of antibiotic resistance were analyzed. These results of our research correlate with other data in the idea of *P. aeruginosa* biofilms formation as a factor in the development of antibiotic resistance (6, 15, 33).

The Center for Disease Control estimates that 65% of all human infections are caused by bacteria with biofilm phenotype and the National Institutes

of Health estimates that this number is closer to 80% (43). Our study indicated the prevalence of *P. aeruginosa* (63.6%) among gram-negative microorganisms isolated from the biological material in patients with CAP. *P. aeruginosa* is characterized by high prevalence and fatality rates (22), equipped with a suite of virulence determinants and a complex regulatory network of intracellular and intercellular signals that allow the bacteria to adapt to antibacterial drugs and evade host defences (32). Multidrug- and totally- drug-resistant strains of *P. aeruginosa* are increasing threats that contribute to high mortality in these patients (22, 27).

The presence of bacterial biofilms complicates the treatment of infectious diseases, in particular pneumonia (17, 26). Biofilm-associated bacteria are involved in a wide range of infections, such as respiratory tract infections, chronically infected wounds, and medical device-associated infections (42). They also promote antibiotic resistance by blocking the access of antibiotics and host immune cells, leading to drug resistance in bacteria (34). The inability of antibiotics to kill biofilm bacteria has been classically attributed to a decreased ability of these agents to penetrate biofilms due to the mechanical and chemical properties of the extracellular matrix. A dense polysaccharide matrix of biofilm was visualized in our study using LSCM.

In this study, we found that all *P. aeruginosa* isolates were resistant to many groups of antimicrobials prescribed to patients. Furthermore, increased tolerance of *P. aeruginosa* biofilms to amikacin and ciprofloxacin was observed. Detection of β -lactam antibiotics effectiveness showed that the effectiveness against actively reproducing bacteria was inversely proportional to the activity of biofilm bacteria, confirmed by other data (22). It was shown that *P. aeruginosa* has high levels of intrinsic resistance to most antibiotics due to limited outer membrane permeability (27).

Respiratory tract infections are a major cause of morbidity and mortality worldwide. Chief among them are infections affecting the lower respiratory tract (25). The outcome of lower respiratory tract infection is also determined by the extent of immune defence and inflammation (26). Pneumonia is a type of acute lower respiratory infection that is common and severe, especially in cases caused by gram-negative microflora, as it is a direct cause of unhealthy aging, decline and death. Although pneumonia results from a microbial infection, the pathogenesis of this disease is found out by the host response (26). The mechanisms responsible for susceptibility must be better elucidated so they can be interrupted. Improved knowledge in these areas may lead to the development of additional comprehensive diagnostic and treatment methods through an in-depth study of mechanisms aimed at reducing mortality in patients with pneumonia.

It should be noted that in 2 cases a septic condition developed, which led to a fatal outcome: during the histological examination, it was found that the

pleura was thickened, stratified in places infiltrated with leukocytes, there was an accumulation of leukocytes with fibrin threads on the surface, its vessels were full of blood. Areas of emphysema with thinning and rupture of interalveolar membranes alternate with atelectasis. In the lumens of the alveoli there is a diffuse purulent exudate, sometimes with fibrin impurities. Individual alveoli are collapsed, there is swollen pink content in the lumens with individual macrophages and a large number of clear erythrocytes. Inter-alveolar membranes are not defined in places, most of them are infiltrated with lymphocytes, plasma cells and alveolar macrophages. The development of sepsis in these patients, can be explained by the predominance of pan-resistant isolates of gram-negative aerobic rod-shaped microorganisms that are highly resistant to antibiotics. Our quantitative analysis showed that pan-resistant isolates of *P. aeruginosa* form biofilms, the OD of which exceeds the OD of biofilms of poly-resistant isolates. The possibility of developing sepsis in the setting of pneumonia is supported by scientific studies by other authors, which indicate that pneumonia is by far the most common cause of sepsis (44, 45).

Finally, information about antibiotic resistance is constantly changing and expanding, thus the survey problems about the development of antibiotic resistance in community-acquired pneumonia should be reconstructed for future research. A greater understanding of this issue will reveal new ways to improve the results of diagnosis and treatment of pulmonary infections.

Conclusion

Studying the structural and functional features of biofilms formation by antibiotic-resistant *P. aeruginosa* isolates established that on the surface of conglomerates consisting of bacterial cells, biofilms are formed according to the classical stages. The first stage (adhesion or sedimentation) is the primary attachment of the pathogen to the substrate. The second stage (fixation) is the final irreversible attachment of cells of microorganisms to the surface. The third stage (coaggregation) is characterized by the formation of microcolonies followed by the synthesis of a polymer matrix

and the formation of a monolayer and microcolonies. The fourth stage is the formation of clusters and a mature biofilm (after the fusion of microcolonies, a three-dimensional structure is formed that can change size and shape). The fifth stage is dispersion (destruction stage) which represents the release of bacteria or the loss of single fragments that spread through the organism and attach to the substrate with the formation of a new biofilm.

Dense biofilms determine the phenotypic variability of *P. aeruginosa* with the development of resistance to antimicrobial drugs, which is an obstacle to the use of antimicrobial therapy.

Acknowledgements: The authors wish to thank all participating hospitals for providing surveillance data and Karazin National University for providing LIVE/DEAD® dye. We thank Miss. Olga Tsikhotska for the English language revision.

Funding: Investigation was performed without any external funding.

Ethic Committee: Meeting of the Department of Microbiology, Virology and Immunology named after D.P.Grynyov, Kharkiv National Medical University (Protocol No. 2, 01/30/2024).

Conflict of Interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

Authors Contribution: MM, AC, OB conceived and designed the study and wrote original manuscript. SM, MM, YM, IM, YK collected and organized the data, collected pictures, provided research materials. RP, AF conceived the idea, analyzed and interpreted data. All the Co-Authors contributed to the interpretation of data and provided critical comments on the manuscript for important intellectual content. All authors have critically reviewed, approved the final draft and are responsible for the content and similarity index of the manuscript.

Reference

- Maharath A, Ahmed MS. Bacterial Etiology of Bloodstream Infections and Antimicrobial Resistance Patterns from a Tertiary Care Hospital in Malé, Maldives. *Int J Microbiol.* 2021 Oct 18;2021:3088202. doi: 10.1155/2021/3088202.
- Bengtsson-palme J, Kristiansson E, Larsson DGJ. Environmental factors influencing the development and spread of antibiotic resistance. *FEMS Microbiology Reviews.* 2018; 42(1):68–80. doi: 10.1093/femsre/fox053.
- Vitomaska-Melnyk AO, Trikhlib VI. Manifestations of pneumonia in the wounded during a full-scale invasion of Ukraine in 2022 according to the data of instrumental examination methods (stand report) UDC 616.9. Ukrainian Military Medical Academy, Kyiv, Ukraine Abstracts of the medical forum Infectious diseases — today's challenges. 2023 Jun;19(3): 193–213. doi: 10.22141/2224- 0586.19.3.2023.1581.
- Torres A, Cilloniz C, Niederman MS et al. Pneumonia. *Nat Rev Dis Primers.* 2021 Apr 8;7(1):25–28. doi: 10.1038 /s41572-021-00259-0.
- Boyer S, Hérisant L, Sherlock G. Adaptation is influenced by the complexity of environmental change during evolution in a dynamic environment. *PLoS Genet.* 2021 Jan 25;17(1):e1009314. doi: 10.1371/journal.pgen.1009314.
- Mulunch A. Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. *Pneumonia.* 2022 May 5;14(1):4. doi: 10.1186 /s41479-022-00096-z.
- Moura-Alves P, Puyskens A, Stinn A et al. Host monitoring of quorum sensing during *Pseudomonas aeruginosa* infection. *Science* 2019 Dec 20;366(6472):eaaw1629. doi: 10.1126/science.aaw1629.
- Lee J, Zhang L. The hierarchy quorum sensing network in *Pseudomonas aeruginosa*. *Protein Cell.* 2015 Jan;6(1):26–41. doi: 10.1007/s13238-014-0100-x.
- Moradali MF, Ghods S, Rehm BH. *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front Cell Infect Microbiol.* 2017 Feb 15;7:39. doi: 10.3389/fcimb.2017.00039.
- Yang D, Hao S, Zhao L, et al. Paeonol attenuates quorum-sensing regulated virulence and biofilm formation in *Pseudomonas aeruginosa*. *Front Microbiol.* 2021 Aug 4;12:692474. doi: 10.3389/fmicb.2021.692474.
- Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. *Pharm Ther.* 2015 Apr 1;40(4):277–283. PMID: 25859123; PMCID: PMC4378521.
- Rutherford ST, Bassler BL. Bacterial quorum sensing: its role in virulence and possibilities for its control. *Cold Spring Harb. Perspect Med.* 2012 Nov 1;2(11):a012427. doi: 10.1101/cshperspect.a012427.
- Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev.* 2005 Oct;18(4):657–86. doi: 10.1128/CMR.18.4.657-686.2005.
- Poirel L, La Rosa JMO, Kieffer N, et al. Acquisition of extended-spectrum beta-lactamase GES-6 leading to resistance to ceftolozane-tazobactam combination in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2018 Dec 21;63(1):e01809-18. doi: 10.1128/AAC.01809-18.
- Subedi D, Vijay AK, Willcox M. Overview of mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*: an ocular perspective. *Clin Exp Optom.* 2018 Mar;101(2): 162–171. doi: 10.1111/cxo.12621.

16. Berrazeg M, Jeannot K, Enguene VY, et al. Mutations in beta-lactamase AmpC increase resistance of *Pseudomonas aeruginosa* isolates to antipseudomonal cephalosporins. *Antimicrob Agents Chemother*. 2015 Oct;59(10):6248-55. doi: 10.1128/AAC.00825-15.
17. Maurice NM, Bedi B, Sadikot RT. *Pseudomonas aeruginosa* biofilms: host response and clinical implications in lung infections. *Am J Respir Cell Mol Biol*. 2018 Apr;58(4):428-439. doi: 10.1165/rcmb.2017-0321TR.
18. Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. *FEMS Microbiol Rev*. 2017 May 1;41(3):276-301. doi: 10.1093/femsre/flux010.
19. Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. *Clin Infect Dis*. 2014 Sep 15;59(Suppl 2):S71-75. doi: 10.1093/cid/ciu392.
20. Cohen NR, Lobritz MA, Collins JJ. Microbial persistence and the road to drug resistance. *Cell Host Microbe*. 2013 Jun 12;13(6):632-642. doi: 10.1016/j.chom.2013.05.009.
21. Papenfort K, Bassler BL. Quorum sensing signal-response systems in Gram-negative bacteria. *Nat Rev Microbiol*. 2016 Aug 11;14(9):576-88. doi: 10.1038/nrmicro.2016.89.
22. Maurice NM, Bedi B, Sadikot RT. *Pseudomonas aeruginosa* biofilms: host response and clinical implications in lung infections. *Am J Respir Cell Mol Biol*. 2018 Apr;58(4):428-439. doi: 10.1165/rcmb.2017-0321TR.
23. Horna G, Ruiz J. Type 3 secretion system of *Pseudomonas aeruginosa*. *Microbiol Res*. 2021 May;246:126719. doi: 10.1016/j.micres.2021.126719.
24. Crabbé A, Jensen PO, Bjarnsholt T, et al. Antimicrobial tolerance and metabolic adaptations in microbial biofilms. *Trends Microbiol*. 2019 Oct;27(10):850-863. doi: 10.1016/j.tim.2019.05.003.
25. Siegel SJ, Weiser JN. Mechanisms of bacterial colonization of the respiratory tract. *Annu Rev Microbiol*. 2015;69:425-44. doi: 10.1146/annurev-micro-091014-104209.
26. Quinton LJ, Walkey AJ, Mizgerd JP. Integrative Physiology of Pneumonia. *Physiol Rev*. 2018 Jul;98(3):1417-1464. doi: 10.1152/physrev.00032.2017.
27. Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol Adv*. 2019 Jan-Feb;37(1):177-192. doi: 10.1016/j.biotechadv.2018.11.013.
28. Flitter BA, Hvorecny KL, Ono E, et al. *Pseudomonas aeruginosa* sabotages the generation of host proresolving lipid mediators. *Proc Natl Acad Sci USA*. 2017 Jan 3;114(1):136-141. doi: 10.1073/pnas.1610242114.
29. Panda SK, Colonna M. Innate lymphoid cells in mucosal immunity. *Front Immunol*. 2019 May 7;10(861). doi: 10.3389/fimmu.2019.00861.
30. Chiang WC, Pamp SJ, Nilsson M, et al. The metabolically active subpopulation in *Pseudomonas aeruginosa* biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms. *FEMS Immunol Med Microbiol*. 2012 Jul;65(2):245-56. doi: 10.1111/j.1574-695X.2012.00929.x.
31. Lopez-Calleja AI, Moralis EM, Medina RN, et al. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* clinical isolates from a Spanish hospital. *Rev Esp Quimioter*. 2019 Feb; 32(1):68-72. PMID: 30547503; PMCID: PMC6372965.
32. Sinha M, Ghosh N, Wijesinghe DS, et al. *Pseudomonas aeruginosa* theft biofilm require host lipids of cutaneous wound. *Ann Surg*. 2023 Mar 1;277(3):634-647. doi: 10.1097/SLA.0000000000005252.
33. Bowler LL, Zhanel GG, Ball TB, et al. Mature *Pseudomonas aeruginosa* biofilms prevail compared to young biofilms in the presence of ceftazidime. *Antimicrob Agents Chemother*. 2012 Sep;56(9):4976-9. doi: 10.1128/AAC.00650-12.
34. Feng W, Sun F, Wang Q, et al. Epidemiology and resistance characteristics of *Pseudomonas aeruginosa* isolates from the respiratory department of a hospital in China. *J Glob Antimicrob Resist*. 2017 Mar;8:142-147. doi: 10.1016/j.jgar.2016.11.012.
35. Ahmed MN, Porse A, Sommer MOA, et al. Evolution of antibiotic resistance in biofilm and planktonic *Pseudomonas aeruginosa* populations exposed to subinhibitory levels of ciprofloxacin. *Antimicrob Agents Chemother*. 2018 Jul 27;62(8):e00320-18. doi: 10.1128/AAC.00320-18.
36. Beaudoin T, Zhang L, Hinz AJ, et al. The biofilm-specific antibiotic resistance gene *ndvB* is important for expression of ethanol oxidation genes in *Pseudomonas aeruginosa* biofilms. *J Bacteriol*. 2012 Jun;194(12):3128-36. doi: 10.1128/JB.06178-11.
37. Livermore DM. Of *Pseudomonas*, porins, pumps and carbapenems. *J Antimicrob Chemother*. 2001 Mar;47(3):247-50. doi: 10.1093/jac/47.3.247.
38. Livermore DM. Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa*: our worst nightmare? *Clin Infect Dis*. 2002 Mar 1;34(5):634-40. doi: 10.1086/338782.
39. Jurado-Martin I, Sainz-Mejias M, McClean S. *Pseudomonas aeruginosa*: an audacious pathogen with an adaptable arsenal of virulence factors. *Int J Mol Sci*. 2021 Mar 18;22(6):3128. doi: 10.3390/ijms22063128.
40. Ozer E, Yaniv K, Chetrit E, et al. An inside look at a biofilm: *Pseudomonas aeruginosa* flagella biotracking. *Sci Adv*. 2021 Jun 11;7(24):eabg8581. doi: 10.1126/sciadv.abg8581.
41. Qin S, Xiao W, Zhou C, et al. *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. *Signal Transduction and Targeted Therapy*. 2022 Jun 25;7(1):199. doi: 10.1038/s41392-022-01056-1.
42. Singh S, Datta S, Narayanan KB, et al. Bacterial exopolysaccharides in biofilms: role in antimicrobial resistance and treatments. *J Genet Eng Biotechnol*. 2021 Sep 23;19(1):140. doi: 10.1186/s43141-021-00242-y.

43. Wolcott R, Dowd S. The role of biofilms: are we hitting the right target? *Plast Reconstr Surg*. 2011 Jun 1;127 (suppl 1):28S–35S. doi: 10.1097/PRS.0b013e3181fca244.
44. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence*. 2014 Jan 1;5(1):4–11. doi: 10.4161/viru.27372.
45. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA*. 2009 Dec 2;302(21):2323–2329. doi:10.1001/jama.2009.1754.

Correspondence:

Received: 13 February 2024

Accepted: 3 July 2024

Olha Bondarenko, PhD

Department of Microbiology, Virology and Immunology
named after prof. D.P. Gryniov

Kharkiv National Medical University

Department of Medicine and Surgery,

University of Parma, G. Rasori Str., 10 Parma, 43125, Italy

E-mail: bondarenkolor84@gmail.com

ORCID: 0000-0002-4808-9513